| 摘要 |
<p>1439742 Nasal influenza vaccine RECHERCHE ET INDUSTRIE THERAPEUTIQUES 3 Feb 1975 [4 Feb 1974] 4535/75 Heading A5B A live influenza virus vaccine suitable for nasal administration comprises, as active ingredient an attenuated influenza type B virus strain recombinant obtained from (i) a vaccinal and attenuated influenza type B virus strain and (ii) another influenza type B virus strain, said recombinant having at least one marker property of said attenuated strain which is not shared by said other strain and the antigenic composition of said other strain. The attenuated strain may be Brigit strain. The recombinant may be influenza type BR5, R22 or R22 strain (ATCC VR787, 788 and 789 respectively). The recombinant may be prepared by combining the attenuated strain and the other strain in the allantoic cavity of embryonated chicken eggs, and isolating the recombinant by selective pressure. The isolate may be grown in the allantoic cavity of chicken eggs, admixed with a stabilizer, e.g. peptone or sugar, and freeze-dried. The vaccine may also include an attenuated influenza type A virus vaccine, e.g. Alice strain (ATCC VR776).</p> |
